This study revealed the distribution of FGFR2 abnormalities in some types of carcinomas and suggested the clinical usefulness of FGFR2 inhibitors for tumors with FGFR2 abnormalities not only fusion but also amplification and mutation. This evidence concerns the gene FGFR2 and carcinoma.